Open AccessTumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
Author(s) -
Joo Young Ha,
Jeong Eun Kim,
Hee Jin Lee,
Jae Ho Jeong,
JinHee Ahn,
Kyung Hae Jung,
Gyungyub Gong,
Eun Young Chae,
Hak Hee Kim,
Il Yong Chung,
Beom Seok Ko,
SungBae Kim
Publication year - 2021
Publication title -
journal of breast cancer/journal of breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 36
eISSN - 2092-9900
pISSN - 1738-6756
DOI - 10.4048/jbc.2021.24.e36
Subject(s) - pertuzumab , trastuzumab , medicine , docetaxel , oncology , carboplatin , human epidermal growth factor receptor 2 , breast cancer , epidermal growth factor receptor , chemotherapy , cancer , cancer research , cisplatin
The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual anti-human epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.